Tirzepatide 1 Year Results: Complete SURMOUNT Data
One year on tirzepatide produces what many consider the most impressive weight loss results ever achieved with a pharmaceutical intervention. The SURMOUNT-1 trial demonstrated average weight loss of 20.9% at the highest dose (15 mg) over 72 weeks, with more than 60% of patients losing 20% or more of their body weight. These results position tirzepatide as the most effective currently available weight loss medication.
Medical Disclaimer: This article is for informational purposes only. Clinical trial results represent averages; individual outcomes vary significantly.
SURMOUNT-1: 72-Week Results by Dose
| Dose | Avg. % Lost | Avg. lbs (230 lb start) | % Achieving 20%+ Loss |
|---|---|---|---|
| 5 mg | -15.0% | ~35 lbs | 36% |
| 10 mg | -19.5% | ~45 lbs | 55% |
| 15 mg | -20.9% | ~48 lbs | 63% |
| Placebo | -3.1% | ~7 lbs | 1.3% |
Tirzepatide vs. Semaglutide: 1-Year Comparison
| Metric | Tirzepatide (15 mg) | Semaglutide (2.4 mg) |
|---|---|---|
| Avg. % body weight lost | -20.9% | -14.9% |
| Patients achieving 20%+ loss | 63% | ~32% |
| HbA1c reduction (T2D) | -2.0 to -2.3% | -1.0 to -1.8% |
| GI discontinuation rate | 4-7% | 7% |
Health Outcomes at 1 Year
| Health Marker | Average Change (15 mg) |
|---|---|
| Waist circumference | -7 to -9 inches |
| Systolic blood pressure | -8 to -12 mmHg |
| Triglycerides | -25 to -35% |
| Fasting insulin | -40 to -60% |
| CRP (inflammation) | -40 to -60% |
Beyond Weight: Quality of Life at 1 Year
Patients on tirzepatide for 12 months consistently report dramatic quality-of-life improvements:
- Physical function: Easier movement, less joint pain, improved stamina.
- Mental health: Improved body image, reduced depression and anxiety symptoms.
- Sleep: Significant improvements in sleep apnea and sleep quality.
- Social life: Increased confidence and willingness to participate in activities.
- Medication reduction: Many patients reduce or eliminate blood pressure and diabetes medications.
Maintaining Results Long-Term
Tirzepatide, like semaglutide, works best as a long-term treatment. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide after 36 weeks regained approximately 14% of their body weight over the following 52 weeks, while those who continued maintained their loss. Continued treatment, potentially at a reduced maintenance dose, is typically recommended for sustained results.
Frequently Asked Questions
How much weight do you lose in 1 year on tirzepatide?
SURMOUNT-1 showed 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg at 72 weeks. At 12 months specifically, approximately 17-21% depending on dose.
What percentage of patients lose over 20% body weight?
36% at 5 mg, 55% at 10 mg, and 63% at 15 mg lost 20% or more in SURMOUNT-1. These are the highest rates seen in any weight loss medication trial.
Is tirzepatide better than semaglutide for weight loss?
Based on clinical trial data, tirzepatide produces greater average weight loss (20.9% vs. 14.9% at maximum doses). Individual responses vary and the best choice depends on your specific situation.
For long-term tirzepatide treatment with clinical monitoring, explore Trimi's treatment programs.
More on GLP-1 Results & Outcomes
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).